Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate

7 Jul 2009

Abstract excerpt

Histone deacetylase inhibitors (HDACi) are potential candidates for therapeutic approaches in cancer and neurodegenerative diseases such as spinal muscular atrophy (SMA)--a common autosomal recessive disorder and frequent cause of early childhood death. SMA is caused by homozygous absence of SMN1. Importantly, all SMA patients carry a nearly identical copy gene, SMN2, that produces only minor levels of correctly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetics and Neurodevelopmental Disorders
Share to Neurogenetic and Muscular Disorders Research
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19584083
DOI: 10.1093/hmg/ddp313

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproatePMID 19584083Read ↗

Combined treatment with the histone deacetylase inhibitor LBH589 and a splice‐switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cellsSemantic proximity Read ↗

Spinal muscular atrophy and therapeutic prospects.Semantic proximity Read ↗

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.Semantic proximity Read ↗

SMN-Inducing Compounds For The Treatment Of Spinal Muscular AtrophySemantic proximity Read ↗

Spinal muscular atrophy: from gene to therapy.Semantic proximity Read ↗

Spinal muscular atrophy: state-of-the-art and therapeutic perspectives.Semantic proximity Read ↗

Type I PRMT inhibitor MS023 promotes <i>SMN2</i> exon 7 inclusion and synergizes with nusinersen to rescue the phenotype of SMA miceSemantic proximity Read ↗

Combining SMN2 splicing modifiers with HDAC6 inhibition greatly improves muscle function and survival in Spinal Muscular AtrophySemantic proximity Read ↗

Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585.Semantic proximity Read ↗

<i>In vitro</i> and <i>ex vivo</i> evaluation of second‐generation histone deacetylase inhibitors for the treatment of spinal muscular atrophySemantic proximity Read ↗

Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug‐like compoundsSemantic proximity Read ↗

Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.